InMed Pharmaceuticals, Inc. (NASDAQ: INM) related to its merger with Mentari Therapeutics, Inc. Upon closing of the proposed transaction, InMed shareholders are expected to own approximately 1.51% of the combined company.
InMed Pharmaceuticals, Inc. (NASDAQ: INM) related to its merger with Mentari Therapeutics, Inc. Upon closing of the proposed transaction, InMed shareholders are expected to own approximately 1.51% of the combined company.